enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Buy” by the ten ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $25.89.

Several brokerages recently weighed in on ENGN. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Raymond James assumed coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target on the stock. UBS Group cut shares of enGene from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. HC Wainwright started coverage on enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Piper Sandler began coverage on enGene in a research note on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target for the company.

enGene Trading Down 5.7 %

NASDAQ ENGN opened at $5.75 on Wednesday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 1-year low of $4.42 and a 1-year high of $18.40. The firm’s fifty day simple moving average is $6.75 and its 200-day simple moving average is $7.17. The company has a market capitalization of $254.42 million, a PE ratio of -9.92 and a beta of -0.65.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, sell-side analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enGene

Several large investors have recently made changes to their positions in ENGN. Wolverine Asset Management LLC bought a new position in enGene in the 3rd quarter worth approximately $37,000. Vontobel Holding Ltd. acquired a new stake in shares of enGene in the fourth quarter worth $69,000. Jane Street Group LLC bought a new position in enGene during the fourth quarter worth $93,000. Toronto Dominion Bank acquired a new position in enGene during the 4th quarter valued at $97,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after purchasing an additional 2,080 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.